DONATE

Seven additional IBEC labs achieve top-level in My Green Lab certification

Seven more research groups at the Institute for Bioengineering of Catalonia (IBEC) have been certified by My Green Lab, reaching the highest rating, the Green Level, for sustainable laboratory practices. With these additions, IBEC core facilities and 70% of the Institute’s laboratories are now certified.

LUMIRIS, an IBEC spin-off, wins the Digital Entrepreneur Award in the Revelation category

Samuel Ojosnegros (left) and Anna Seriola (right) receive the award from Jorid Borda (centre). / Image: Catalunya Ràdio

The 7th edition of the Premis Emprenedors Digitals (Digital Entrepreneur Awards), organised by the Catalunya Ràdio programme, took place on Wednesday 18 June at the Antigua Fábrica Damm in Barcelona. The award recognises companies that have demonstrated exceptional growth and innovation in their field.

Embryos can eliminate bacterial infections before forming their immune system, a new research shows

The work, led by a team from the CSIC and IDIBELL, with the collaboration of IBEC, manages to visualise how embryonic cells eliminate bacterial infections, before the formation of the immune system. The research describes a mechanism of phagocytosis similar to that used by white blood cells, and reveals that this mechanism is also present in human embryos.

Printing proteins to recreate the gut in the lab

An IBEC-led study describes the development of an innovative method to control the formation of crypt-like structures and villi in the intestine using a contact protein printing technique. This model will make it possible to study in detail key processes such as cell regeneration or changes associated with diseases such as cancer and chronic inflammatory disorders.

LUMIRIS, the IBEC spin-off that has raised €6 million to transform assisted reproduction

This spin-off from the Institute for Bioengineering of Catalonia has developed a non-invasive technology that analyses the metabolism of human embryos to select the most suitable ones for implantation. This innovation promises to significantly reduce the time and number of treatment cycles required for in vitro fertilisation. The success of LUMIRIS’ technology has led to a new round of investment of €1.5 million, bringing the total to €6 million since the company was founded in 2023.